Swittons Introduces IoT-Enabled Smart Devices for Pharmaceutical Labs
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives.
Swittons, a P360 company, introduced a new line of Internet of Things (IoT)-enabled smart devices for pharmaceutical labs. The devices work to automate laboratory workflows between people and existing digital lab equipment, systems, and solutions.
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives. Additionally, the new devices are compatible with laboratory information management systems, eDOC, and ticketing systems and feature a backend portal and reporting system.
“There are profound changes taking place in the area of life science research and development,” said Anupam Nandwana, Swittons’ CEO and founder, in an Aug. 11, 2020 company press release. “Driven by technological advances and the development of precision medicines, these modernization initiatives are designed to propel laboratory efficiencies into the future, allowing scientists to spend more time on science. This has changed the very concept of what the lab is, and Swittons is a key part of that evolution.”
Source: Swittons
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
